Headache & Migraine
Conference Coverage
e-TNS device passes at-home test
A phase 3 study showed the Cefaly device was particularly effective against most bothersome migraine symptoms.
Conference Coverage
A large proportion of migraine patients are not offered preventive treatment
Among patients eligible for preventive therapy, more than a third were not offered this option, fewer than 10% were currently taking preventive...
Conference Coverage
Combination therapy may benefit patients with migraine
A retrospective chart review suggests adding an anti-CGRP antibody to onabotulinumtoxinA boosts benefit.
Conference Coverage
Almost half of patients with migraine are reluctant to seek care
Common reasons for failure to seek treatment included believing that migraine was not severe enough to warrant a consultation, worries about cost...
Conference Coverage
Telemedicine for headache visits had high patient satisfaction
Most patients who used telemedicine said they would like to continue using it after the pandemic, though the study also revealed barriers to care...
Conference Coverage
Fremanezumab fails posttraumatic headache test
The anti-CGRP antibody provided no benefit, despite success in other headache types.
Conference Coverage
Nitroglycerine lends insight into migraine
Sometimes underappreciated method allows better study of premonitory symptoms.
News
FDA expands rimegepant indication to include migraine prevention
Rimegepant is currently the only migraine medication approved to both treat acute migraine attacks and help prevent future migraine attacks.
Literature Review
Race, ethnicity, and socioeconomics are often barriers to migraine care
People of African descent and Latinx ethnicity tend to fare worse than other people of color and their White counterparts.
From the Journals
Transcranial brain stimulation can modulate placebo and nocebo experiences
It remains to be seen if this method could eventually alter chronic pain.
Conference Coverage
Rituximab benefits seen in neuropsychiatric lupus
Findings from the largest prospective study of rituximab for NPSLE to date show signs of rituximab’s efficacy in reducing neuropsychiatric disease...